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INTRODUCTION
Chronic graft-versus-host disease (GVHD) is an impor-
tant cause of morbidity and mortality in patients undergoing
allogeneic bone marrow transplantation (BMT) [1,2].
Chronic GVHD typically occurs after 100 days after trans-
plantation and develops in 40% to 50% of transplant recipi-
ents [1,3,4]. The incidence of chronic GVHD is higher
when the bone marrow donor is unrelated to the recipient
[5]. Clinically, chronic GVHD is characterized by multisys-
tem disease that frequently has clinical features resembling
those of autoimmune disease. Clinical manifestations
include sclero d e rmatous and lichenoid skin changes,
esophageal dysmotility, intestinal malabsorption, cholestasis,
sicca syndrome, polyserositis, bronchiolitis obliterans, and
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ABSTRACT
C h ronic graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation.
Both the disease and the medications used to treat it are associated with significant morbidity and mort a l i t y. The
manifestations of chronic GVHD often resemble those of autoimmune disorders. Hydro x y c h l o roquine (HCQ) is
a 4-aminoquinoline antimalarial drug used for the treatment of autoimmune diseases. HCQ interf e res with anti-
gen processing and presentation, cytokine production, and cytotoxicity and is synergistic with cyclosporine and
t a c rolimus in vitro. Forty patients with stero i d - resistant or steroid-dependent chronic GVHD were enrolled in a
phase 2 trial of HCQ 800 mg (12 mg/kg) per day. Three complete responses and 14 partial responses were seen
in 32 evaluable patients (53% response rate). All responders tolerated a >50% reduction in their steroid dose
while receiving HCQ. Clinical response occurred at a median of 8 weeks (range, 4 to 24 weeks). No hemato-
logic, hepatic, renal, or retinal toxicity was associated with HCQ. In light of its mechanisms of action, clinical
activity for GVHD, and low toxicity profile, HCQ may be useful in a multiagent approach for the treatment of
extensive chronic GVHD. 
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autoantibodies. These manifestations may result in severe
disability and death [3,4,6]. 
C h ronic GVHD is usually treated with cort i c o s t e ro i d s
alone or with cyclosporine. Primary treatment results in
complete response rates of 33% to 37% for patients with
extensive chronic GVHD [7,8]. Salvage therapy for failure
of primary treatment results in complete response rates of
11% to 38% for patients with re f r a c t o ry extensive disease
[8-10]. Treatment of chronic GVHD is sometimes effective
in controlling disease manifestations, but long-term mor-
bidity (from both the disease and treatment) is signific a n t ,
and mortality rates remain approximately 30% to 50% [3,4].
Because of the limited success of current therapies for
c h ronic GVHD, alternative agents with diff e rent mecha-
nisms of action need to be evaluated.
H y d ro x y c h l o roquine (HCQ), a lysosomotropic 4-amino-
quinoline antimalarial drug, has been used to treat autoim-
mune disorders for more than 30 years [11]. HCQ is partic-
ularly effective for mucocutaneous manifestations of
autoimmune disease and is also useful for decreasing the
dose of prednisone needed to control autoimmune diseases
[12]. HCQ is generally well tolerated. The most common
side effects are gastrointestinal (GI) symptoms, and these
occur infrequently. The most worrisome toxicity of HCQ is
retinopathy resulting in visual field deficits. Retinal toxicity
is very uncommon and is related to the daily and cumulative
dose and to the duration of therapy [13]. Retinopathy rarely
occurs before 2 years of treatment, even at high doses [14].
HCQ affects several steps of the immune re s p o n s e
involved in chronic GVHD. It differs from chloroquine by
only a single hydroxyl group, and the 2 drugs are believed to
function similarly. Chloroquine has been used for the
majority of studies of mechanisms of action because it is
m o re readily available for laboratory re s e a rch. HCQ is a
weak base that interf e res with antigen processing and pre-
sentation through the major histocompatibility complex
(MHC) class II pathway by raising lysosomal and endosomal
pH [15]. HCQ also reduces production of the proinflamma-
t o ry cytokines interleukin (IL)-1 and IL-6 and tumor
n e c rosis factor (TNF)-α [16,17]. HCQ inhibits, in a dose-
dependent fashion, the production of IL-1 and IL-6 by
monocytes stimulated with lipopolysaccharide and the pro-
duction of IL-6 by T cells stimulated with phytohemagglu-
tinin (PHA) or immobilized anti-CD3 antibody [18].
Cyclosporine and HCQ (chloroquine in some experi-
ments) are synergistic in suppressing in vitro pro l i f e r a t i v e
T-cell responses to endogenous antigens, such as minor his-
tocompatibility complex (MiHC) and MHC antigens, and
to exogenous antigens such as tetanus toxoid [19,20].
Chloroquine is also synergistic with tacrolimus (FK506) in
s u p p ressing proliferative T-cell responses to MiHC and
MHC antigens in vitro. The synergy appears to be related
not to suppression of T-cell cytokine production [21] but to
the effects of HCQ on antigen processing and presentation.
HCQ reduces the cytotoxicity, proliferation, and TNF-α
p roduction resulting from allorecognition [22]. Reduction of
T N F -α p roduction is important, because TNF-α– s e c re t i n g
m a c rophages have been implicated in the pathogenesis of
GVHD [23]. In vitro data have been demonstrated to be clini-
cally relevant by HCQ’s ability to prevent the development of
acute [24] and chronic (Gilman and Yankelovich, unpublished
data) GVHD in murine models. Based on preclinical data and
the fact that HCQ is a well-established drug for the tre a t m e n t
of autoimmune disease, with mechanisms of action and toxici-
ties that do not overlap with those of commonly used
i m m u n o s u p p ressive drugs, a phase 2 study was conducted to
assess the efficacy and toxicity of HCQ in patients with
c h ronic GVHD. 
MATERIALS AND METHODS
Eligibility Criteria
Patients 1 to 60 years of age with stero i d - resistant or
s t e roid-dependent chronic GVHD were eligible for tre a t-
ment. Steroid resistance was defined as a lack of impro v e m e n t
following a trial of steroids either alone or in combination with
other immunosuppressive medications. Steroid dependence
was defined as the need for ≥20 mg/d prednisone (≥0.5 mg/kg
per day if weight <50 kg) for more than 6 weeks, necessitated
by a flare of chronic GVHD when the prednisone was
t a p e red. Patients were also eligible if they were experiencing
toxicity from immunosuppressive medications (eg, severe
h y p e rtension, decreased renal function, or pancre a t i t i s ) .
Response Criteria
Patients were evaluable for response after re c e i v i n g
1 month of HCQ (HCQ takes 4 to 8 weeks to reach steady-
state concentrations [11]). Response criteria were defined as
follows: complete response (CR), complete clinical re s o l u-
tion of all GVHD manifestations; partial response (PR),
complete clinical resolution of at least 1 organ, clinical
i m p rovement (≥50%) in at least 1 organ, or tapering of
p rednisone or cyclosporine by ≥50% (ie, medication dose
reduction [MDR]) without worsening of GVHD in any
o rgan; and no response (NR),  no significant clinical
improvement in GVHD or no tapering of medication after
3 months with HCQ levels ≥5 µmol/L. 
Treatment Plan
The study was perf o rmed as a multi-institutional phase 2
trial. HCQ 800 mg daily (12 mg/kg per day if weight <50 kg)
was given orally. Hydro x y c h l o roquine (Plaquenil) was pro-
vided by Sanofi Wi n t h rop Pharmaceuticals (New York, NY). 
Dose adjustments were made for patients with cholestas i s
(dose decreased by 25% or 50% for bilirubin >6 or >12 t i m e s
the upper limit of normal, respectively), renal impairm e n t
(dose decreased by 25% for creatinine ≥3 times the upper
limit of normal), and poor absorption (dose increased by
50% for profuse diarrhea, documented malabsorption of
other immunosuppressive drugs, or GI GVHD). The ration-
ale for these dose adjustments is as follows: (1) HCQ has an
unusually large volume of distribution secondary to extensive
accumulation in tissues [11]; (2) elimination occurs thro u g h
e n t e rohepatic recycling and shedding of pigmented tissues,
such as skin; and (3) approximately 20% to 50% of the dru g
u n d e rgoes renal clearance [25,26]. Unless other immunosup-
p ressive drugs were causing significant side effects, curre n t
i m m u n o s u p p ressive medication doses remained the same
until the patient had a complete response. 
Patients remained on HCQ until they achieved a com-
plete response and were weaned off other immunosuppre s s i o n
or until they completed 1 year of HCQ therapy at >5 µm o l / L.
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Patients were discontinued from the study for grade III or IV
toxicity, according to the National Cancer Institute toxicity
scale, or for significant retinal toxicity. HCQ levels were
monitored and the HCQ dose was adjusted (ie, increased by
25%) to achieve a steady-state whole-blood level of 5 to 25
µmol/L. The maximum HCQ dose was 1000 mg (14.5
mg/kg if weight <50 kg). HCQ levels were determined by
h i g h - p e rf o rmance liquid chromatography [25]. 
T h ree laboratories perf o rmed the assay over the course of
the study. These laboratories were directed by Dr. S. Khalil,
N o rth Dakota State University, Fargo, ND; Dr. D. Furst, Vi r-
ginia Mason Research Center, Seattle, WA; and Dr. I. Wa i n e r,
M o n t real General Hospital, Montreal, Quebec, Canada.
Clinical Monitoring
Patients had a history and physical examination every
2 weeks for a total of 6 examinations, and then examinations
were conducted every 4 weeks. Complete blood cell counts,
liver function tests, and blood chemistry tests were per-
f o rmed every 2 weeks for a total of 6 times, and then every
4 weeks. Ophthalmologic examinations with visual field test-
ing were perf o rmed every 3 months for early detection of
retinal toxicity. Biopsies to confirm chronic GVHD were
p e rf o rmed as clinically indicated and were not re q u i red to
confirm clinical responses.
I n f ormed Consent
Before study entry, all patients or their guardians signed
consent forms approved by the institutional review board.
RESULTS
Patient Characteristics
F o rty patients were enrolled in the study between August
1994 and January 1999. One patient had limited chro n i c
GVHD (liver), and the remainder had extensive chro n i c
GVHD. All patients had clinical manifestations of GVHD at
study entry. Data re g a rding acute GVHD were available for
29 of the 32 evaluable patients, and 20 had a history of grade
II to IV acute GVHD. Five of the evaluable patients had
received donor lymphocyte infusions before the onset of
c h ronic GVHD. Biopsy confirmation of chronic GVHD was
available for 73% of the evaluable patients. The diagnosis of
c h ronic GVHD for the remaining patients was based on typi-
cal clinical manifestations that responded to immunosuppre s-
sion and worsened with decreased immunosuppression. 
Responses 
T h i rty-two patients were evaluable for response; 8 patients
w e re not evaluable because of an inadequate therapeutic
trial (ie, <1 month of treatment). Of the nonevaluable
patients, 5 died within 1 month of starting protocol therapy;
the cause of death was thrombotic thrombocytopenic pur-
pura (2 patients), liver failure (1 patient), sepsis (1 patient),
and hemorrhage after liver biopsy (1 patient). The other 3
patients who were not evaluable for response were lost to
follow-up (1 patient) or stopped therapy because of GI toxi-
city (2 patients). 
The following data refer to the 32 evaluable patients.
Patients were enrolled in the study because of resistant dis-
ease (17 patients), resistant disease and toxicity fro m
i m m u n o s u p p ressive medications (3 patients), dependence
on steroids (7 patients), and dependence on steroids and
toxicity from immunosuppressive medications (5 patients).
Toxicity from other medications at study entry included
s e v e re cushingoid features (7 patients), steroid myopathy
(5 patients), hypertension (4 patients), decreased re n a l
function (3 patients), severe osteopenia (3 patients), and pan-
c reatitis (1 patient). Eighteen of the 20 patients who were
e n rolled with resistant disease had failed at least 2 months of
therapy with prednisone and cyclosporine or tacro l i m u s .
The 2 patients who were enrolled in the study within 2 months
of the diagnosis of chronic GVHD had pro g ressive onset
of chronic GVHD while receiving immunosuppre s s i v e
d rugs. Although some patients were enrolled for stero i d
dependence or toxicity rather than steroid resistance, all
patients had evaluable clinical manifestations of chro n i c
GVHD at the time of study entry. Characteristics of evalu-
able patients are summarized in Table 1.
T h ree complete and 13 partial clinical responses were
seen, for a clinical response rate of 50% (16 of 32). Steroid
dose was decreased by ≥50% in all responders. One patient
Table 1. Characteristics of Evaluable Study Patients
n 32
Age
Children 20
Adults 12
Donor type
Matched related 17
Unrelated 11
Haploidentical related 04
Onset of chronic GVHD *
Progressive 13
Quiescent 15
De novo 04
Median duration of chronic GVHD before study entry 3 mo
(range, 1 wk
to 75 mo)
Immunosuppression at study entry
Steroids (prednisone/methylprednisolone) 31
Cyclosporine 18
Tacrolimus 06
Azathioprine 04
Mycophenolate mofetil 04
Psoralen plus ultraviolet A phototherapy 01
Treatment group†
Resistant 17
Resistant/toxicity 03
Dependent 07
Dependent/toxicity 05
*Progressive indicates that acute GVHD has not resolved before onset
of chronic GVHD; quiescent, acute GVHD has resolved before onset
of chronic GVHD; de novo, no history of acute GVHD.
†Resistant indicates no significant improvement with previous therapy;
dependent, improvement in chronic GVHD with previous therapy but
dependent on a significant amount of immunosuppression to control
GVHD; toxicity, significant toxicity from other immunosuppressive
medications. Three patients listed as resistant and 5 patients listed as
dependent were entered into the study for these reasons as well as for
toxicity.
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who did not qualify as having a clinical response (although
he had improvement of skin involvement) had a part i a l
response (ie, a ≥50% decrease in the dose of pre d n i s o n e
[MDR]). Four patients (13%) had improvement in GVHD
but did not qualify as having a response, and therefore were
counted as nonresponders. Seven patients (22%) had no
response. Six patients (19%) experienced progression of dis-
ease while receiving treatment. Two of these six had addi-
tional therapy for progressive disease early in the course of
t reatment and were subsequently considered to be re s p o n-
ders. Details are provided below. 
The overall survival rates as of November 1999 were 75%
for responders, with a median follow-up of 32 months (range,
10 to 60 months), and 40% for nonresponders (median follow-
up, 30 months, range 21 to 40 months). Clinical re s p o n s e s
w e re seen at a median of 8 weeks (range, 4 to 24 weeks). The
median duration of response was 9 months (range, 2.5 to 14
months). All responses were sustained during the study.
I m p rovement by organ system is shown in Table 2. Details of
individual patient responses are provided in Table 3.
One patient (005) experienced both a response of GI
GVHD and pro g ression of liver GVHD soon after start i n g
HCQ. Her steroid dose was doubled and remained at the
i n c reased dose for 4 months. She is considered a part i a l
responder because of her GI response and because her liver
GVHD resolved and then remained quiescent as she was
weaned off steroids. Patient 025 had an unusual pre s e n t a t i o n ,
with severe acute GVHD occurring at 9 months after trans-
plantation. He demonstrated pro g ressive onset of chro n i c
GVHD. He received antithymocyte globulin 10 days before
study entry and 4 days after beginning the study, and his
cyclosporine was changed to tacrolimus 5 days after begin-
ning the study. His chronic GVHD manifestations did not
begin to resolve until 1 month after study entry. He tolerated
marked weaning of his steroids without a fla re of GVHD.
The 32 evaluable patients included many patients at
high risk for failure, with 15 (47%) recipients of matched
u n related or haploidentical donor bone marro w, 13 (41%)
with pro g ressive onset of GVHD, and 14 (44%) with a
platelet count of <100,000/µL at study start. Responders
were seen in all groups, including 10 of 15 recipients (67%)
of matched unrelated or haploidentical donor bone mar-
ro w, 5 of 13 patients (38%) with pro g ressive onset of
GVHD, and 9 of 14 patients (64%) with a platelet count of
< 1 0 0 , 0 0 0 /µL at study entry. Responses were seen in 10 of
20 c h i l d ren (50%) and 6 of 12 adults (50%). Patient
response by reason for study entry is provided in Table 4.
For the entire group of 40 patients, reasons for discon-
tinuing protocol therapy included completion of pro t o c o l
therapy (10 patients), death (9 patients), pro g ressive disease (7
p a t i e n t s ) , toxicity (6 patients), patient decision (3 patients),
lack of response (2 patients), physician decision (1 patient),
and loss to follow-up (1 patient). One patient remains on
study (duration of treatment, 11.5 months). Of the 3 patients
who decided to discontinue the study, 2 did so because of
inadequate rapidity of response; and 1 patient left the tre a t-
ment center. The physician’s decision for discontinuation
was based on re c u rrent infections, although the incidence of
infection before and during the study did not diff e r.
Toxicity 
T h i rty-nine patients were evaluable for toxicity; 1 patient
was lost to follow-up. The duration of HCQ tre a t m e n t
ranged from 2 days to 16.5 months (median, 4.5 months;
mean, 6 months). The duration of treatment for the 17
responders ranged from 3 to 16.5 months (median, 10.5
months; mean, 10 months). Infections occurred in 10 of 39
patients (26%) and were fatal in 4. Four patients had re c u r-
rent infections before study entry. There were 10 episodes of
b a c t e remia in 3 patients. The organisms isolated included
gram-positive cocci (2), gram-negative rods (6), and C a n d i d a
spp (2). Eleven patients died during the study or within 1
month of the end of the study. Five of the deaths occurre d
within 1 month of starting protocol therapy. Causes of death
included pneumonia/pneumonitis (4 patients), pro g re s s i v e
c h ronic GVHD/thrombotic microangiopathy (3 patients),
sepsis (1 patient), liver failure (1 patient), pulmonary hemor-
rhage (1 patient), and hemorrhage after liver biopsy (1
p a t i e n t ) .
Due to the relatively high dose of HCQ used, a major
concern in our study was retinal toxicity. Standard therapy
with HCQ is 400 mg (6.5 mg/kg) daily, although the dose
used in our study is approved for several months of tre a t-
ment until disease control is achieved. Seventeen patients
were treated for ≥6 months, and some remained in the study
for as long as 16.5 months. No retinal toxicity was seen. 
The most common side effects were GI symptoms,
which occurred in 3 patients (9%). These symptoms
included nausea (2 patients), diarrhea (2 patients), and
cramps (1 patient). One patient already had GI symptoms
from chronic GVHD, and therefore the role of HCQ was
u n c l e a r. One patient complained of nausea when his dose
was increased but tolerated the drug well when it was
reduced to the starting dose. 
HCQ has also been re p o rted to rarely cause a neuro p a t h y
or myopathy [27]. Without muscle biopsy, myopathy can be
d i fficult to diff e rentiate from the proximal myopathy caused
by steroids. Polymyositis caused by chronic GVHD can also
cause proximal muscle weakness, but patients with p o l y m y o s i-
tis usually have an elevated creatine kinase (CK) level [28].
T h ree patients were suspected, on clinical grounds, to have
H C Q - related neuropathy (1 patient) or myopathy (2 p a t i e n t s ) .
Two of the patients were receiving HCQ despite pre v i o u s
Table 2. Sites of Improvement and Clinical Responses by Organ System
Clinical Response
Site Improvement* (CR + PR)†
Skin 9/13 5/13
Oral mucosa 6/13 5/13
Gastrointestinal tract 2/8 2/8
Liver 11/15 9/15
Lung 2/9 1/9
Thrombocytopenia 8/12 7/12
*Improvement, but not sufficient to qualify as a partial response.
†Response criteria: CR indicates complete resolution of this manifesta-
tion of chronic graft-versus-host disease; PR, improvement of at least
50% in area of skin or mucosal involvement or in elevations of hepatic
transaminase or bilirubin levels or at least doubling of platelet count or
50% improvement in other organs as measurements allow. 
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Table 3. Details of Responses*
Time From
Immuno- Chronic
Age, Donor suppression at GHVD to Treatment Platelets Type of
Patient y Type Study Entry Study Entry Group† <100,000 µL Onset‡ Involved Sites Responses§
01 22 MUD P, C, A 14 mo Resistant No Quiescent Li, F PR liver
02 26 MFD P, C, A 5 mo Resistant Yes Quiescent Lu, M, PS, Plts NE (hemolysis/TM; 
HCQ 3 5 doses)
03 26 MUD P, C, A 10 mo Dependent No Quiescent SR, O CR skin rash, oral
04 31 MFD P, C 20 mo Resistant Yes Progressive SL, SS, O, Li, Plts NE (death; infection)
05 04 MUD P, T 3 mo Resistant Yes Quiescent GI, Li, Plts PR GI
06 02 Haplo P, C 2 wk Dependent/ No Quiescent SL, O, GI, Li, PR lichenoid skin, 
toxicity Plts (TM) oral, liver, Plts (TM)
07 18 MFD P, T, U 32 mo Resistant No De novo SL, O, Li, sicca NE (itching; GI symptoms)
08 39 MUD P, C 12 mo Resistant No Quiescent SR PR (on basis of MDR; 
skin rash improved)
09 09 Haplo MP 3 wk Dependent/ Yes Quiescent Lu, Plts (TM) PR platelets (TM)
toxicity
10 1.5 MUD MP 9 mo Resistant/ Yes Quiescent GI, Plts (TM) PD thrombotic 
toxicity microangiopathy
11 09 MUD P, C 54 mo Resistant No De novo Lu NR
12 13 MFD P, C 6 mo Resistant Yes De novo Lu (BO), Plts PD lung
13 34 MFD MP 3 mo Dependent No Quiescent Li, sicca NR (liver improved)
14 12 MFD P, C 10 mo Resistant No Progressive SL, SS, O, NR (lichenoid skin 
Lu, sicca and oral improved)
15 36 MFD P 4.5 mo Resistant Yes Progressive SL, O, Plts (TM) NR (lichenoid 
skin improved)
16 14 MFD P, C 3.5 mo Dependent No Progressive Li CR liver
17 35 MFD P 2 mo Resistant Yes Progressive SL, SS, O, PR platelets (lichenoid
Plts, sicca skin improved)
18 16 MFD P, C 2 mo Resistant No Quiescent Li, Lu PR liver
19 13 MUD MP, C 2 mo Resistant/ Yes Progressive SR, O, GI, Li, NE (death; hemorrhage 
toxicity Lu, Plts with liver biopsy)
20 12 MUD P, C 14 mo Resistant No De novo O, Lu, sicca NR (small 
improvement lungs)
21 38 MFD P, C 1 wk Dependent Yes Quiescent O, Li, Plts PR liver 
(platelets improved)
22 20 MFD (5/6) P 8 mo Resistant/ No Quiescent SL, SS, O PR oral
toxicity
23 33 MFD P, C 2 mo Dependent No Progressive SR, Li, Lu (BO) NR 
24 16 MFD MP, T 3.5 wk Dependent Yes Progressive Li, sicca, Plts PR liver
25 06 MFD (5/6) MP, C 1 wk Resistant Yes Progressive Li, O, sicca, Plts PR liver, oral, 
sicca, platelets 
26 38 MUD P, T 1 wk Resistant Yes Progressive GI, Li, Plts (TM) NE (death, TM)
27 08 Haplo P, C 13.5 mo Resistant No Quiescent SR, SS, sicca PR skin rash
28 46 MFD MP, T, MMF 2 wk Resistant Yes Progressive Li NR (liver improved)
29 35 MUD MP, T 10 mo Resistant Yes Quiescent GI, Li, Plts NE (death; liver failure)
30 46 MFD P, T 10 mo Resistant No Quiescent SR, SS, O, GI, NE (lost to follow-up)
Li, sicca, Lu
31 37 MFD (5/6) P, T, A 27 mo Resistant No Quiescent SL, O, sicca PD
32 02 MFD P, C 3.5 wk Resistant No Progressive GI, Li NR
33 48 MFD MMF 75 mo Resistant No Progressive SS, GI NR
34 30 MFD P, T 28.5 mo Resistant No Quiescent SS, Li, sicca NE (nausea and GI upset)
35 08 Haplo P, C, A 29 mo Dependent/ No Progressive O, GI, Lu NR
toxicity
36 06 MUD P, C 10 wk Dependent/ Yes Progressive SR, Li, Plts (TM) PR skin rash, 
toxicity liver, platelets
37 10 MUD P, C, MMF 22 mo Resistant/ Yes Quiescent AIHA, Plts, GI NR
toxicity
38 07 MUD (4/6); MP, T 1 mo Dependent/ Yes Quiescent O, GI, Li, Lu, PR oral, GI, liver, 
cord toxicity Plts, AIHA lung, platelets, AIHA
39 06 MFD MP, T, MMF 3 mo Resistant No Progressive O, Li PD (lung)
40 12 MUD P 9 wk Dependent Yes De novo SR, Plts CR skin rash, platelets
*A indicates azathioprine; AIHA, autoimmune hemolytic anemia; BO, bronchiolitis obliterans, C, cyclosporine; cord, umbilical cord blood; F, fasciitis; GI, gastrointestinal;
GVHD, graft-versus-host disease; haplo, haploidentical related donor; Li, liver; Lu, lung; M, myositis; MFD, matched related donor; MMF, mycophenolate mofetil; MP,
methylprednisolone; MUD, matched unrelated donor; O, oral; P, prednisone; Plts, thrombocytopenia; PS, polyserositis; S, skin; sicca, sicca syndrome (dry eyes/mouth); SL,
lichenoid changes; SR, skin rash; SS, sclerodermatous changes; T, tacrolimus; TM, thrombotic microangiopathy; U, psoralen plus ultraviolet A phototherapy (PUVA).
†Resistant indicates no significant improvement with previous therapy; dependent, dependent improvement in chronic GVHD with previous therapy but dependent on a
significant amount of immunosuppression to control GVHD; toxicity, significant toxicity from other immunosuppressive medications.
‡Progressive indicates acute GVHD that has not resolved before onset of chronic GVHD; quiescent, acute GVHD that has resolved before onset of chronic GVHD; de
novo, no history of acute GVHD.
§Response criteria: improvement indicates improvement, but not sufficient to qualify as a partial response; CR, complete response; PR, partial response, defined as
improvement of at least 50% in area of skin or mucosal involvement or in elevations of hepatic transaminases or bilirubin, at least doubling of platelet count, 50%
improvement in other organs as measurements allow, or tapering of prednisone or cyclosporine by ≥50% (medication dose reduction); NR, no response, defined as no
significant clinical improvement in GVHD or drug taper after 3 mo with HCQ level ≥5 µmol/L; PD, progressive disease; NE, not evaluable.
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removal from the study, and their toxicity data are pro v i d e d
only because of the data’s potential clinical importance. In 1
patient, a muscle biopsy specimen demonstrated changes con-
sistent with HCQ-related myopathy and without the infla m-
mation suggestive of chronic GVHD-related myositis. None
of the patients had an elevated CK level. Import a n t l y, all 3 of
these patients had poor renal function (creatinine at least 2
times the upper limit of normal), and in 2 patients, very high
levels of HCQ were documented. 
Other re p o rted side effects of HCQ included pru r i t u s
(1 patient) and intravascular hemolysis (1 patient). The itching
and GI symptoms were responsible for the first of these
patients discontinuing study. Of note, the patient was re c e i v-
ing psoralen plus ultraviolet A phototherapy (PUVA) at the
same time. The episode of hemolysis was associated with clini-
cal and laboratory findings consistent with thrombotic thro m-
b ocytopenic purpura related to chronic GVHD. It began
after 5 doses of HCQ and persisted for weeks after the discon-
tinuation of HCQ. Of note, 3 patients with thro m b o t i c
m i c roangiopathy received HCQ and improved. The other 4
patients with thrombotic microangiopathy (including the
patient who received only 5 doses of HCQ) worsened while
on HCQ. 
DISCUSSION
F o rty patients with stero i d - resistant or stero i d - d e p e n-
dent chronic GVHD were treated with HCQ. In 16 of the
32 evaluable patients (50%), GVHD improved clinically,
and patients were able to have the dose of at least 1 immuno-
s u p p ressive drug decreased by at least 50%. One patient
who did not qualify as a responder on a clinical basis
(although he did have improvement of skin involvement)
had a partial response (MDR) based on a ≥50% decrease in
the dose of prednisone. Four patients demonstrated
improvement in their GVHD but did not qualify as having a
response and were counted as nonresponders. 
I m p rovement with HCQ was most notable for skin, oral,
and liver GVHD, and for a rise in platelet count. Some
patients demonstrated improvement that did not qualify as a
response (Table 2). The fact that skin GVHD improved in 9
of 13 cases is consistent with re p o rts of a prominent effect of
HCQ on the cutaneous manifestations of autoimmune dis-
ease [12]. Oral GVHD improved in 6 of 13 patients, and liver
GVHD improved in 11 of 15 patients. Thro m b o c y t o p e n i a
i m p roved in 8 of 12 patients. The response of thro m b o c y-
topenia is potentially important. Sullivan et al. [8] showed
that patients with a platelet count <100,000/µL at the end of
9 months of therapy had a significantly higher mortality rate.
Lung GVHD improved in only 2 of 9 cases, which was disap-
pointing in light of the high response rate to HCQ noted in
patients with autoimmune diffuse interstitial pneumonitis
[29]. The response data for lung GVHD must be interpre t e d
with caution because no patient had biopsy-proven lung
GVHD. Patients were diagnosed on the basis of pulmonary
function tests and, in some cases, with high-resolution com-
puted tomography scans [30-32].
HCQ was very well tolerated. No hematologic, hepatic,
renal, or retinal toxicity was associated with HCQ. The most
common side effects were GI symptoms, which occurred in
3 patients (9%). HCQ-related myopathy was suspected in
2 patients and documented in 1. HCQ-related neuro p a t h y
was suspected in 1 patient. As noted above, 2 of the patients
w e re on HCQ despite prior removal from the study, and
their toxicity is provided only because of its potential clinical
i m p o rtance. Import a n t l y, all 3 of these patients had poor
renal function (ie, creatinine levels at least 2 times the
upper limit of normal), and in 2 patients, very high levels of
HCQ were documented. Future trials will study dose re d u c-
tions in patients whose creatinine level is >1.5 times the
upper limit of norm a l .
Although the results with HCQ are pre l i m i n a ry, they
compare favorably with those of other trials of second-line
agents in similar groups of patients. Table 5 provides a com-
parison of outcomes in published clinical trials of systemic
therapy for re f r a c t o ry chronic GVHD. Comparisons must
be interpreted with the knowledge that the studies were per-
f o rmed several years apart, and that diff e rences exist in
patient risk factors. Our study population had a larger per-
centage of patients with unrelated or haploidentical donors
than did the studies listed in Table 5. It should be noted that
the study by Rovelli et al. [33] included only children. In a
trial of thalidomide for 37 patients with extensive chro n i c
GVHD, re p o rted only as an abstract, Browne et al. [36]
re p o rted a lower response rate for patients with unre l a t e d
donors (30% versus 47%) and a much lower response rate
for adults than for children (18% versus 50%). In our
s t u d y, 44% of the evaluable patients had platelet counts
< 1 0 0 , 0 0 0 /µL. Data for comparison are not provided in
Table 5 because they were available only for the study by
Rovelli et al. [33], in which 54% of patients had platelet
counts <100,000/µL. Our study was the first multicenter
trial of therapy for chronic GVHD, in contrast to the other
studies, which were conducted at single institutions. Finally,
eligibility and response criteria differ among the studies
listed in Table 5. In our study, the eligibility criteria and
median duration of treatment for chronic GVHD before
study entry (median duration of treatment, 3 months; range,
1 week to 75 months) were similar to those in the study of
thalidomide by Parker et al. [10] (median duration of treat-
Table 4. Response by Treatment Group
Resistant* D e p e n d e n t †
Complete response — 3
Partial response
Clinical 7† 6†
Medication dose reduction >50% 8† 6†
No response 8 3
Progressive disease 4 —
Not evaluable 8 —
Responses in evaluable patients 8/20 (40%) 9/12 (75%)
*Resistant indicates no significant improvement with previous therapy.
†Dependent, improvement in chronic GVHD with previous therapy but
dependent on a significant amount of immunosuppression to control
GVHD. Three patients listed as resistant and 5 patients listed as depen-
dent were entered into study for these reasons as well as toxicity. All
patients qualified as a partial response on the basis of both a clinical
response and a medication dose reduction except for 1 patient in the resis-
tant group who qualified on the basis of a medication dose reduction only. 
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ment, 4.5 months; range, 1 to 42 months); the duration of
initial therapy for chronic GVHD before study entry that
was necessary for GVHD to be considered “refractory” was
not defined for the remainder of the studies listed in Table 5.
The response criteria used for our study were similar to
those used in all of the studies in Table 5, with the exception
of the study by Sullivan et al. [8]. In their study, a complete
response was defined as complete clinical resolution of
chronic GVHD manifestations and a negative biopsy result
for GVHD; a partial response was defined as complete clini-
cal resolution of chronic GVHD manifestations and a posi-
tive biopsy result for GVHD.
Infectious complications in our study were similar to
those in a study of thalidomide reported by Vogelsang et al.
[9]. In their study with 23 patients with refractory chronic
GVHD, complications included pneumonitis/pneumonia (5
patients), varicella zoster infection (2 patients), bactere m i a
(1 patient), and other infections (4 patients).
The toxicities of HCQ in our study—very infre q u e n t
GI symptoms and neuromyopathy—compare favorably with
those of other drugs used for second-line treatment of
GVHD (eg, thalidomide and clofazimine). It may be possi-
ble to avoid neuromyopathy by reducing the HCQ dose in
patients with marked renal dysfunction. Thalidomide is
associated with neuro p a t h y, sedation, constipation, skin
rash, and neutropenia [10]. Clofazimine is associated with
GI and ocular symptoms and with a reversible re d - b ro w n
hyperpigmentation of the skin and conjunctiva [34]. HCQ
has much less toxicity than steroids and may be useful when
added to initial therapy for GVHD as a stero i d - s p a r i n g
agent, similar to its use in autoimmune diseases.
Some mechanisms of action of HCQ differ from the
direct effect on T lymphocytes seen with other immunosup-
pressive drugs. HCQ interferes with antigen processing and
presentation by raising lysosomal and endosomal pH, and it
also reduces production of the pro i n f l a m m a t o ry cytokines
IL-1, IL-6, and TNF-α [15-17]. IL-6 lowers endosomal
pH, resulting in increased presentation of cryptic (con-
cealed) epitopes. Cryptic epitopes of endogenous pro t e i n s
appear to be low-affinity peptides that, when presented to
T cells by antigen-presenting cells (APCs), can lead to the
development of autoimmune disease. Normally, APCs pres-
ent immunodominant epitopes, which promote tolerance of
self-peptides. Chloroquine is a potent inhibitor of the shift
in epitope repertoire to expression of cryptic antigenic epi-
topes [37]. It has been proposed that the increase in endoso-
mal and lysosomal pH caused by lysosomotropic amines,
including HCQ, may reduce binding of low-affinity, cryptic
cellular peptides to MHC class II, allowing for preferential
binding of high-affinity (immunodominant) self-peptides to
MHC class II [38]. Chloroquine has also been demonstrated
to interfere with antigen processing and subsequent presen-
tation in the context of class II HLA molecules to CD4+
T cells by inhibiting dissociation of the chaperone protein,
invariant chain, from MHC class II and thereby preventing
antigenic peptide binding [39].
HCQ appears to have activity for chronic GVHD that
is at least comparable to that of other agents used as seco n d -
line therapy. HCQ has mechanisms of action that diff e r
f rom at least some of the commonly used immunosuppre s-
sive drugs. It has also been shown to be synergistic with
cyclosporine and tacrolimus in vitro. It is well tolerated
and has infrequent toxicities that do not overlap with those
of other immunosuppressive drugs. For these re a s o n s ,
HCQ may be useful as part of a multiagent approach for
the treatment of extensive chronic GVHD. A randomized,
p l a c e b o - c o n t rolled, double-blind phase 3 trial will soon be
initiated to determine whether the addition of HCQ to a
s t a n d a rd regimen of prednisone and cyclosporine will be
beneficial in the treatment of newly diagnosed extensive
c h ronic GVHD.
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